CLINICAL TRIALS PROFILE FOR SHR6390
✉ Email this page to a colleague
Clinical Trials for SHR6390
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02671513 ↗ | A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients | Unknown status | Beijing Cancer Hospital | Phase 1 | SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced melanoma patients by using a "3+3" dose escalation.Preliminary efficacy will be also investigated in this study. |
| NCT02671513 ↗ | A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients | Unknown status | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced melanoma patients by using a "3+3" dose escalation.Preliminary efficacy will be also investigated in this study. |
| NCT02684266 ↗ | A Study of SHR6390 in Advanced Solid Tumor Patients | Unknown status | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | SHR6390 is a small molecular, oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced solid tumor patients by using a "3+3" dose escalation.Preliminary efficacy will be also investigated in this study. |
| NCT03480256 ↗ | Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer | Unknown status | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | The aim of the study is to assess the safety and tolerability of SHR6390 combined with pyrotinib in the patients with Her-2 positive advanced gastric cancer. |
| NCT03480256 ↗ | Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer | Unknown status | Peking University | Phase 1 | The aim of the study is to assess the safety and tolerability of SHR6390 combined with pyrotinib in the patients with Her-2 positive advanced gastric cancer. |
| NCT03481998 ↗ | A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | Active, not recruiting | Jiangsu HengRui Medicine Co., Ltd. | Phase 1/Phase 2 | This is a phase IB/II clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole or Fulvestrant. Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for study. |
| NCT03601598 ↗ | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | Unknown status | Jiangsu HengRui Medicine Co., Ltd. | Phase 1/Phase 2 | This is a Phase Ib/II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With SHR6390 (a CDK4/6 Inhibitor) in Patients With Advanced Colorectal Cancer, Non-small Cell Lung Cancer and Hepatocellular Carcinoma. The study was designed in two stages, the first stage was the tolerance observation stage, and the second stage was the curative effect expansion stage. The first part of the study is the Dose-finding Phase designed to establish the safety of SHR-1210 Combination With SHR6390 at different dose Levels(150mg QD or 100mg QD ). The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses . This study aims to evaluate the safety and efficacy of SHR-1210 combination with SHR6390 in the treatment of advanced CRC,NSCLC and HCC. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for SHR6390
Condition Name
Clinical Trial Locations for SHR6390
Clinical Trial Progress for SHR6390
Clinical Trial Phase
Clinical Trial Sponsors for SHR6390
Sponsor Name
